112 related articles for article (PubMed ID: 38769179)
1. Letter to the editor for the article "Patient's self‑reported quality of life as a prognostic factor in metastatic renal cell carcinoma initially treated with TKI: nomogram proposal".
Huang X; Wang L; Yang X; Lu J; Yang G; Chi H
World J Urol; 2024 May; 42(1):340. PubMed ID: 38769179
[No Abstract] [Full Text] [Related]
2. Patient's self-reported quality of life as a prognostic factor in metastatic renal cell carcinoma initially treated with TKI: nomogram proposal.
Lendínez-Cano G; Vilches-Arenas Á; Congregado-Ruíz B; Medina-López R
World J Urol; 2024 Apr; 42(1):267. PubMed ID: 38678165
[TBL] [Abstract][Full Text] [Related]
3. Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.
Park JY; Lee JL; Baek S; Eo SH; Go H; Ro JY; Cho YM
Hum Pathol; 2014 Jul; 45(7):1437-44. PubMed ID: 24784922
[TBL] [Abstract][Full Text] [Related]
4. HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients.
Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
Cancer Immunol Immunother; 2018 Jan; 67(1):79-87. PubMed ID: 28918459
[TBL] [Abstract][Full Text] [Related]
5. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
6. Identification of a 6-Gene Signature Associated with Resistance to Tyrosine Kinase Inhibitors: Prognosis for Clear Cell Renal Cell Carcinoma.
Li Q; Yang W; Lu M; Zhang R
Med Sci Monit; 2020 Dec; 26():e927078. PubMed ID: 33296352
[TBL] [Abstract][Full Text] [Related]
7. Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor.
Cai W; Wang Z; Cai B; Yuan Y; Kong W; Zhang J; Chen Y; Liu Q; Huang Y; Huang J; Xue W
Int J Clin Oncol; 2020 Feb; 25(2):338-346. PubMed ID: 31720994
[TBL] [Abstract][Full Text] [Related]
8. Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy.
Shinohara N; Obara W; Tatsugami K; Naito S; Kamba T; Takahashi M; Murai S; Abe T; Oba K; Naito S
Cancer Sci; 2015 May; 106(5):618-26. PubMed ID: 25711777
[TBL] [Abstract][Full Text] [Related]
9. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
Bukowski RM
Clin Genitourin Cancer; 2007 Sep; 5(6):359-61. PubMed ID: 17956708
[No Abstract] [Full Text] [Related]
10. Cabozantinib in renal cell carcinoma: only a METEOR or a rising star?
Bersanelli M; Buti S
Acta Biomed; 2016 Sep; 87(2):224-5. PubMed ID: 27649009
[TBL] [Abstract][Full Text] [Related]
11. Systemic treatment options for untreated patients with metastatic clear cell renal cancer.
Molina AM; Motzer RJ; Heng DY
Semin Oncol; 2013 Aug; 40(4):436-43. PubMed ID: 23972707
[TBL] [Abstract][Full Text] [Related]
12. Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
Zhou X; Fu G; Zu X; Xu Z; Li HT; D'souza A; Tulpule V; Quinn DI; Bhowmick NA; Weisenberger DJ; Liang G; Chen J
Urol Oncol; 2022 Jan; 40(1):12.e13-12.e22. PubMed ID: 34454823
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
[TBL] [Abstract][Full Text] [Related]
14. Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors.
He L; Liu Y; Han H; Liu Z; Huang S; Cao W; Liu B; Qin Z; Guo S; Zhang Z; Lin M; Jiang X; Lin C; Li Y; Yao K; Dong P; Zhou F
Am J Clin Oncol; 2020 Jan; 43(1):58-63. PubMed ID: 31651452
[TBL] [Abstract][Full Text] [Related]
15. Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors.
Beuselinck B; Pans S; Bielen J; De Wever L; Noppe N; Vanderschueren G; De Keyzer F; Baldewijns M; Lerut E; Laenen A; Verbiest A; Roussel E; Albersen M; Vandecaveye V
Acta Oncol; 2020 Jul; 59(7):818-824. PubMed ID: 32297532
[No Abstract] [Full Text] [Related]
16. Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
J Urol; 2016 Nov; 196(5):1363-1370. PubMed ID: 27288695
[TBL] [Abstract][Full Text] [Related]
17. Treatable causes of diarrhoea in patients on tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Lightowlers SV; Greef B; Eisen T; Matakidou A; Fife K; Cameron EA
Ann Oncol; 2019 Jan; 30(1):150-151. PubMed ID: 30358823
[No Abstract] [Full Text] [Related]
18. The role of tyrosine kinase inhibitors in the treatment of renal cell carcinoma with brain metastases.
Aytekin A; Ciltas A; Sahinli H; Benekli M
J BUON; 2016; 21(1):281-2. PubMed ID: 27061562
[No Abstract] [Full Text] [Related]
19. Editorial Comment on Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy.
Ishihara H; Takagi T
Int J Urol; 2024 May; 31(5):534-535. PubMed ID: 38299686
[No Abstract] [Full Text] [Related]
20. Editorial comment to Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy.
Yuasa T
Int J Urol; 2024 May; 31(5):534. PubMed ID: 38297407
[No Abstract] [Full Text] [Related]
[Next] [New Search]